Saudi multidisciplinary panel proposes a comprehensive CRMD management framework centered on semaglutide, addressing screening gaps, care coordination, and access barriers.
10-15% weight reductionSemaglutide's demonstrated multi-organ benefits support its role in integrated CRMD management
What the researchers found
Saudi consensus panel recommends integrated CRMD management with semaglutide as a cornerstone therapy, citing robust evidence across glycemic, weight, cardiovascular, renal, and hepatic outcomes.
Why it matters
Saudi Arabia faces high metabolic disease prevalence. Integrated management frameworks with proven therapies like semaglutide could significantly reduce disease burden.
How the study worked
Literature review and multidisciplinary expert consensus from Saudi endocrinologists, cardiologists, nephrologists, and hepatologists.
What this study cannot tell us
Consensus report — reflects expert opinion rather than new data; Saudi-specific context may limit broader applicability.
How to read the evidence
Consensus report based on literature review — provides practical guidance but is not a systematic review or original research.
When this study was published
Published 2026 in Diabetes Therapy. Based on current evidence and Saudi healthcare context.
The bigger picture
Country-specific implementation frameworks are essential for translating global clinical trial evidence into practical, culturally appropriate care models.
Questions still open
- How will semaglutide access be expanded within Saudi Arabia's healthcare system?
- Can this CRMD framework be adapted for other Middle Eastern countries?
Common questions
What is cardiorenal metabolic disease?
Why is semaglutide highlighted as a key treatment?
Read the original research
Developing a Comprehensive Approach for Managing Cardiorenal Metabolic Diseases (CRMD) in Saudi Arabia: Thinking beyond Single Disease-Literature Review and Multidisciplinary Consensus Report.
Diabetes therapy : research, treatment and education of diabetes and related disorders, 17(2), 165-183
Citation
Alshaikh, Abdulrahman; Alshehri, Ali; Alzubaidi, Lamya; Elbadawi, Hussein; Alsaeed, Abdulghani; Almehthel, Mohammed; Aldahash, Raed; Alsabaan, Fahad; Alotaibi, Metib; Alghamdi, Khalid; Alamri, Hussein; Bakhsh, Abdulmohsen; Evans, Marc; Issak, Emad R; Alsifri, Saud. (2026). Developing a Comprehensive Approach for Managing Cardiorenal Metabolic Diseases (CRMD) in Saudi Arabia: Thinking beyond Single Disease-Literature Review and Multidisciplinary Consensus Report.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 17(2), 165-183. https://doi.org/10.1007/s13300-025-01826-4